



For Immediate Release
Bill Wells – 404-281-7490

Dr. Mark Atkinson Named to DiaKine Therapeutics' Scientific Advisory Board

Dr. Atkinson is one of the world's most cited experts in diabetes research

CHARLOTTESVILLE, VA (April 3, 2007) -- DiaKine Therapeutics, Inc., a developer of drugs designed to treat diabetes and other immune-related diseases via a novel approach, today announced the appointment of Dr. Mark Atkinson to its Scientific Advisory Board.

Dr. Atkinson is an internationally recognized authority on multiple aspects pertaining to type 1 diabetes, with particular interests in disease prediction and prevention. From 1991 to 2002, he was the fifth most cited authority of over 65,000 investigators in the world in all categories of diabetes.

"I am excited about the potential of DiaKine's drugs to treat diabetes by protecting insulin producing cells and restore the body's natural insulin producing capabilities," said Dr. Atkinson. "The work that Dr. Jerry Nadler and his team have done in the field seeking to control one of the main causes of diabetes puts DiaKine in a leading position to help eradicate this dreaded disease."

"Dr. Atkinson is without question, one of the leading international experts in the field of immunology of type 1 diabetes," said Dr. Nadler. "His advice and counsel will be extremely valuable to DiaKine in helping us to develop immune modulators to safely arrest autoimmune damage to insulin producing cells of the body."

"Dr. Atkinson is one of the world's top diabetes researchers and we are pleased that he has chosen to work with DiaKine as we race to bring our small molecule immune modulators to the patients who most need them," said Keith Ignatz, President, and CEO of DiaKine.

Dr. Atkinson is the Sebastian Family Eminent Scholar for Diabetes Research at The University of Florida. He also holds positions of Director for The Center for Immunology and Transplantation and co-Director for The Diabetes Center of Excellence at that institution. The author of over 175 publications, Dr. Atkinson has over 23 years of investigation into the field of type 1 (insulin dependent)

###MORE###

diabetes. Dr. Atkinson has been the recipient of multiple scientific and humanitarian based awards for these efforts. He currently oversees \$4 million in annual diabetes research. Dr. Atkinson has been a key member of the scientific leadership at organizations such as the Juvenile Diabetes Research Foundation, serving as director of the Scientific Review Committees.

Drugs being developed by Diakine modulate cytokines, part of the body's immune system, which mistakenly attack normal organs and tissue and cause diseases such as; Diabetes and Multiple Sclerosis. Research by Dr. Nadler and his collaborators published in 2006 showed that controlling certain cytokines can arrest the progression of, or reverse, type 1 diabetes in an animal model.

About DiaKine --

DiaKine Therapeutics, Inc. is a development-stage company commercializing novel immune modulators initially targeting the treatment of autoimmune and inflammatory diseases such as diabetes and related complications. These new drugs regulate cytokines, part of the body's immune system, which mistakenly attack normal organs and tissue and cause inflammation. The Company's first product, IsletLife-LSF Media 1 is designed to improve the viability and insulin producing capabilities of harvested islet cells prior to transplant, potentially improving the success rate of the procedure. Additional therapeutics under development by DiaKine include: adjunct therapy to islet cell transplants, halting the progression of type 1 diabetes in newly diagnosed adults, treatment and prevention of Latent Autoimmune Diabetes of Adults (LADA), treatment and prevention of insulin requiring type 2 diabetic, treatment and prevention of diabetes complications. For more information, visit www.diakine.com.

###END###